This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Augmedix Valuation

Is AUGX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AUGX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AUGX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AUGX's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for AUGX?

Key metric: As AUGX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for AUGX. This is calculated by dividing AUGX's market cap by their current revenue.
What is AUGX's PS Ratio?
PS Ratio2.3x
SalesUS$51.58m
Market CapUS$116.16m

Price to Sales Ratio vs Peers

How does AUGX's PS Ratio compare to its peers?

The above table shows the PS ratio for AUGX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.5x
OPRX OptimizeRx
1x9.0%US$85.7m
LFMD LifeMD
1.4x19.0%US$280.2m
FORA Forian
3.2x11.1%US$62.7m
MPLN MultiPlan
0.1x1.7%US$118.0m
AUGX Augmedix
2.3x20.6%US$116.2m

Price-To-Sales vs Peers: AUGX is expensive based on its Price-To-Sales Ratio (2.3x) compared to the peer average (1.6x).


Price to Sales Ratio vs Industry

How does AUGX's PS Ratio compare vs other companies in the US Healthcare Services Industry?

11 CompaniesPrice / SalesEstimated GrowthMarket Cap
MPLN MultiPlan
0.1x1.7%US$118.05m
HCTI Healthcare Triangle
0.3xn/aUS$5.04m
ICCT iCoreConnect
0.4xn/aUS$4.34m
ISPC iSpecimen
0.4xn/aUS$4.08m
AUGX 2.3xIndustry Avg. 2.1xNo. of Companies11PS01.63.24.86.48+
11 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: AUGX is expensive based on its Price-To-Sales Ratio (2.3x) compared to the US Healthcare Services industry average (2.1x).


Price to Sales Ratio vs Fair Ratio

What is AUGX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AUGX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.3x
Fair PS Ratio1.2x

Price-To-Sales vs Fair Ratio: AUGX is expensive based on its Price-To-Sales Ratio (2.3x) compared to the estimated Fair Price-To-Sales Ratio (1.2x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AUGX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$2.93
0%
19.7%US$3.50US$2.35n/a2
Nov ’25n/a
US$2.93
0%
19.7%US$3.50US$2.35n/a2
Oct ’25US$2.35
US$2.73
+16.3%
19.8%US$3.50US$2.35n/a3
Sep ’25US$2.32
US$2.73
+17.8%
19.8%US$3.50US$2.35n/a3
Aug ’25US$2.26
US$2.73
+20.9%
19.8%US$3.50US$2.35n/a3
Jul ’25US$0.93
US$3.33
+258.4%
7.1%US$3.50US$3.00n/a3
Jun ’25US$0.92
US$3.33
+263.1%
7.1%US$3.50US$3.00n/a3
May ’25US$2.53
US$6.10
+141.1%
19.7%US$8.00US$5.00n/a5
Apr ’25US$4.02
US$6.13
+52.4%
23.4%US$8.00US$4.50n/a4
Mar ’25US$4.57
US$7.00
+53.2%
8.7%US$8.00US$6.50n/a4
Feb ’25US$4.51
US$7.00
+55.2%
8.7%US$8.00US$6.50n/a4
Jan ’25US$5.85
US$7.25
+23.9%
11.4%US$8.00US$6.00n/a4
Dec ’24US$5.63
US$7.67
+36.2%
6.1%US$8.00US$7.00n/a3
Nov ’24US$4.40
US$7.13
+61.9%
12.5%US$8.00US$6.00n/a4
Oct ’24US$5.15
US$6.63
+28.6%
12.4%US$8.00US$6.00US$2.354
Sep ’24US$5.02
US$6.63
+32.0%
12.4%US$8.00US$6.00US$2.324
Aug ’24US$4.22
US$6.38
+51.1%
15.1%US$8.00US$5.50US$2.264
Jul ’24US$4.81
US$6.38
+32.5%
15.1%US$8.00US$5.50US$0.934
Jun ’24US$3.81
US$6.38
+67.3%
15.1%US$8.00US$5.50US$0.924
May ’24US$3.00
US$6.25
+108.3%
17.4%US$8.00US$5.00US$2.534
Apr ’24US$1.74
US$5.00
+187.4%
14.1%US$6.00US$4.00US$4.024
Mar ’24US$1.68
US$4.75
+182.7%
17.5%US$6.00US$4.00US$4.574
Feb ’24US$1.58
US$4.75
+200.6%
17.5%US$6.00US$4.00US$4.514
Jan ’24US$1.56
US$4.75
+204.5%
17.5%US$6.00US$4.00US$5.854
Dec ’23US$1.18
US$4.88
+313.1%
15.2%US$6.00US$4.00US$5.634
Nov ’23US$1.58
US$4.88
+208.5%
15.2%US$6.00US$4.00US$4.404

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies